Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Charles River Laboratories cooperation agreement with Elliott
We are advising Charles River on the agreement
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Centogene $49 million follow-on offering
Davis Polk advised Centogene N.V. on its $49 million follow-on public offering of 3,500,000 of its common shares, consisting…
Revolution Medicines $179.4 million follow-on offering
Davis Polk advised the underwriters in connection with a public offering of 6,900,000 shares of common stock of…
Ocumension Therapeutics HK$1.55 billion IPO and HKEX listing
Davis Polk advised the underwriters in the initial public offering of Ocumension Therapeutics on the Hong Kong Stock…
Shenzhen Hepalink Pharmaceutical Group HK$4.05 billion IPO
Davis Polk advised Shenzhen Hepalink Pharmaceutical Group Co., Ltd. in connection with its initial public offering and…
Oryzon Genomics €20 million private placement
Davis Polk advised Oryzon Genomics, S.A. on its private placement of approximately 7,273,000 of its ordinary shares pursuant…
1Life Healthcare $296 million secondary offering
Davis Polk advised the representatives of the several underwriters in connection with the $296 million SEC-registered…
Magenta Therapeutics $69 million follow-on offering
Davis Polk advised the joint book-running managers and representatives of the underwriters in connection with the $69…
Editas Medicine $215.6 million stock offering
Davis Polk advised the sole book-running manager in connection with the $215.6 million common stock offering of 6,900…
Abbott Laboratories $1.3 billion notes offering
Davis Polk advised the joint book-running managers on an SEC-registered offering by Abbott Laboratories of $650 million…
Acadia Healthcare $450 million high-yield notes offering
Davis Polk advised the representative of the initial purchasers of a Rule 144A/Regulation S offering by Acadia Healthcare…